Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study.
Fiche publication
Date publication
août 2024
Journal
Archives of cardiovascular diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PAPATHANASSIOU Dimitri
Tous les auteurs :
Costa J, El-Ali A, Morland D, Dejust S, Papathanassiou D, Nazeyrollas P, Metz D
Lien Pubmed
Résumé
Transthyretin amyloid cardiomyopathy (ATTR-CM) can manifest as rhythm disorders, heart failure, but also valvular degeneration. Despite aortic stenosis (AS) being prevalent among the elderly, data on ATTR-CM prevalence and outcome in patients with AS undergoing transaortic valve implantation (TAVI) remain scarce.
Mots clés
Amyloid transthyretin cardiomyopathy, Bone scintigraphy, Heart failure, Severe aortic stenosis, Transaortic valve implantation
Référence
Arch Cardiovasc Dis. 2024 08 8;: